AI and computational modeling are reducing reliance on animal testing by simulating human biology, improving drug safety and ...

Businesses want to be available to provide for employees and be competitive. They want workers to be able to go to the HR ...

In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

Amid the usual hustle before a big medical conference or industry trade show, editors are often buried under a flood of news ...

Following the company’s announcement of lackluster results from both its Phase III trials, Novo’s shares dropped nearly 9% pre-market, a significant shift the company hasn’t seen in its shares since ...

Each step in the patient journey, benefit verification, prior authorization, fulfillment, and adherence, creates a potential failure point when systems don’t communicate. In many first-generation ...

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about ...

Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to ...

As affordability, access, and transparency reshape U.S. healthcare, manufacturers are rapidly redefining direct-to-patient drug distribution as a core strategic capability, one that demands fully ...

In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis ...

Tesaro confirmed its litigation against AnaptysBio in the Delaware Chancery Court in a press release on its website, ...